GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
71.46
+0.52 (+0.73%)
At close: 4:00PM EDT

71.46 0.00 (0.00%)
After hours: 4:29PM EDT

Stock chart is not supported by your current browser
Previous Close70.94
Open70.96
Bid71.45 x 2200
Ask71.50 x 900
Day's Range70.35 - 71.57
52 Week Range64.27 - 89.54
Volume5,053,055
Avg. Volume7,261,040
Market Cap92.917B
Beta1.30
PE Ratio (TTM)27.18
EPS (TTM)2.63
Earnings DateJul 24, 2018 - Jul 30, 2018
Forward Dividend & Yield2.28 (3.20%)
Ex-Dividend Date2018-06-14
1y Target Est85.77
Trade prices are not sourced from all markets
  • 2 High-Flying Biotech Stocks With Even More Room to Grow
    Motley Fool6 hours ago

    2 High-Flying Biotech Stocks With Even More Room to Grow

    These two red-hot biotechs are showing no signs of slowing down.

  • Bloomberg7 hours ago

    Glaxo Venture's Lofty Goal in HIV: Eclipse Gilead as Top Player

    GlaxoSmithKline Plc’s HIV venture wants to use less burdensome forms of treatment to unseat rival Gilead Sciences Inc. and become the top player in the $26 billion-a-year market in the mid-2020s. “If our pipeline and our competitors’ pipelines play out as we’re expecting, that’s our aim,” Deborah Waterhouse, chief executive officer of ViiV Healthcare, told journalists at a briefing Wednesday in London. Glaxo and partner Pfizer Inc. are taking on Gilead with a strategy to develop two-drug HIV combinations rather than the three-drug regimens that have been the standard for many years.

  • GSK takes billion-dollar drug fight with Gilead to top AIDS meeting
    Reuters8 hours ago

    GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

    GlaxoSmithKline (GSK.L) is taking its fight with Gilead Sciences (GILD.O) for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment. The drugmakers are touting rival strategies for fighting the AIDS virus, with GSK betting that a shift to using two drugs rather than the standard three will boost its market share, while Gilead sticks with the tried and tested triple approach. Deborah Waterhouse, head of GSK's majority-owned HIV business ViiV Healthcare, aims to overtake Gilead as market leader in the $26 billion-a-year (19.8 billion pounds) HIV market by the mid-2020s, assuming the gamble on two-drug combinations pans out.

  • Reuters9 hours ago

    GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

    GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment. The drugmakers are touting rival strategies for fighting the AIDS virus, with GSK betting that a shift to using two drugs rather than the standard three will boost its market share, while Gilead sticks with the tried and tested triple approach. Deborah Waterhouse, head of GSK's majority-owned HIV business ViiV Healthcare, aims to overtake Gilead as market leader in the $26 billion-a-year HIV market by the mid-2020s, assuming the gamble on two-drug combinations pans out.

  • 3 Great Reasons to Buy Gilead Sciences
    Motley Foolyesterday

    3 Great Reasons to Buy Gilead Sciences

    This down-and-out biotech stock could be ready to rebound soon.

  • 1 Under-the-Radar Dividend Growth Stock to Buy Right Now
    Motley Fool3 days ago

    1 Under-the-Radar Dividend Growth Stock to Buy Right Now

    Gilead Sciences has quietly matured into a top dividend growth stock.

  • Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
    Motley Fool5 days ago

    Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers

    These two small biotechs with promising NASH drugs could attract several big suitors.

  • Barrons.com5 days ago

    Big Biotech Set for Earnings Blowout?

    Earlier this year, Oppenheimer's Hartaj Singh argued that earnings expectations were too high for big biotech companies heading into the first-quarter reporting season. Ahead of the reports, due out in mid-July, Singh argues that fundamentals for large-cap biotech, as well as sector sentiment are "slowly but surely improving," leading him to believe that the stocks could outperform, led by Gilead Sciences (GILD), Alexion Pharmaceuticals (ALXN), and Vertex Pharmaceuticals (VRTX). For Gilead, he's upbeat about a more stable pricing environment for hepatitis C treatments, while investors are getting more interested in the company's "budding" immunology and nonalcoholic steatohepatitis (NASH) franchises, setting up an attractive risk-reward profile going into the second quarter.  Alexion reported "stellar" first-quarter earnings, and Singh sees another strong quarter ahead, and he wonders "when the Street will start giving management credit for relentless execution." Vertex is one of his favorite large-cap biotechs, and he sees a good report ahead, along with an update about the progress of its cystic-fibrosis drugs.

  • Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
    Zacks5 days ago

    Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

    Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

  • Glaxo Pops But Analysts Say It's Unlikely To Swipe Gilead Share In HIV
    Investor's Business Daily6 days ago

    Glaxo Pops But Analysts Say It's Unlikely To Swipe Gilead Share In HIV

    GlaxoSmithKline popped Thursday after its two-drug HIV treatment proved non-inferior to a three-drug regimen using medicine from Gilead Sciences. But analysts say Glaxo is unlikely to get much share from Gilead.

  • NASH Space in Focus as Galmed (GLMD) Posts Positive Data
    Zacks6 days ago

    NASH Space in Focus as Galmed (GLMD) Posts Positive Data

    Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.

  • GSK's two-drug HIV treatment meets main goal in late stage studies
    Reuters6 days ago

    GSK's two-drug HIV treatment meets main goal in late stage studies

    The combination of dolutegravir and lamivudine was shown to be as effective as a dolutegravir-based combination of three drugs, GSK's majority-owned ViiV Healthcare said on Thursday. It said its push for two-drug regimens addressed long-term toxicity concerns of people living with HIV by reducing the number of medicines. Rival Gilead Sciences in February won U.S. Food and Drug Administration approval for Biktarvy, a triple-combination HIV treatment, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market.

  • Reuters6 days ago

    GSK's two-drug HIV treatment meets main goal in late stage studies

    GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field. The combination of dolutegravir and lamivudine was shown to be as effective as a dolutegravir-based combination of three drugs, GSK's majority-owned ViiV Healthcare said on Thursday. It said its push for two-drug regimens addressed long-term toxicity concerns of people living with HIV by reducing the number of medicines.

  • GlobeNewswire6 days ago

    Consolidated Research: 2018 Summary Expectations for Encana, Netflix, Veon, The Walt Disney, Gilead Sciences, and Cloudera — Fundamental Analysis, Key Performance Indications

    NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Encana ...

  • ACCESSWIRE6 days ago

    Free Technical Reports on Gilead Sciences and Three Additional Biotech Equities

    On Wednesday, June 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Geron Corp. (NASDAQ: GERN), Gilead Sciences Inc. (NASDAQ: GILD), Global Blood Therapeutics Inc. (NASDAQ: GBT), and GlycoMimetics Inc. (NASDAQ: GLYC).

  • Valeant Pharmaceuticals’ Valuation on June 8
    Market Realist9 days ago

    Valeant Pharmaceuticals’ Valuation on June 8

    As we discussed earlier, Valeant Pharmaceuticals (VRX) reported a non-GAAP EPS of $0.88 on revenues of ~$2.0 billion during the first quarter. Valeant had a 5.4% decline in its year-over-year revenues during the first quarter due to a 9% decrease in operating revenues. The decrease was partially offset by the favorable impact of foreign exchange—compared to revenues of ~$2.1 billion during the first quarter of 2017.

  • CNBC9 days ago

    Gilead Sciences’ Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia

    FOSTER CITY, Calif.---- Gilead Sciences, Inc. announced today that John McHutchison, MD, Chief Scientific Officer and Head of Research and Development, has been appointed an Officer of the Order of Australia in recognition of his“ distinguished service to medical research in gastroenterology and hepatology, particularly through the development of treatments...

  • Business Wire9 days ago

    Gilead Sciences’ Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia

    Gilead Sciences, Inc. announced today that John McHutchison, MD, Chief Scientific Officer and Head of Research and Development, has been appointed an Officer of the

  • See what the IHS Markit Score report has to say about Gilead Sciences Inc.
    Markit12 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILD

  • Motley Fool13 days ago

    Should You Stick With Gilead Sciences?

    Declining sales increase the stakes for Gilead's most-promising R&D projects.

  • Barrons.com13 days ago

    Gilead: The Turnaround Is Happening This Year

    Jefferies Michael Yee recently sat down with Gilead Sciences (GILD) management, and the meeting reinforced his bullish thesis on the stock, that a turnaround is "happening this year." He writes that Gilead executives, including the chief executive, remain confident that the company would hit a trough this year and then resume growth, which will continue into 2019. Yee reiterated a Buy rating and $95 price target on the shares today, writing that Gilead is still his "best large-cap idea" and that its turnaround and recovery offer a different narrative than other large biotechs, where the concern is mostly about generic or biosimilar risks in the coming years.

  • Investopedia13 days ago

    Gilead's Hot Stock May Cool Fast

    Gilead Sciences, Inc. ( GILD) has been on a roll recently with shares rising by over 10% since May 7, easily outpacing the sector's rise of 7.5%, as measured by the iShares NASDAQ Biotechnology ETF (IBB). The company reported earnings that were 11.25% below estimates coming in at $1.48 per share. The technical chart shows a gap created when the stock price dropped 8% from its close on May 1.

  • Gilead Collaborates with Hookipa for HBV and HIV Therapies
    Zacks14 days ago

    Gilead Collaborates with Hookipa for HBV and HIV Therapies

    Gilead Sciences (GILD) collaborates with Hookipa Biotech AG for the development of immunization technologies for HBV and HIV diseases.

  • Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO
    Zacks14 days ago

    Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO

    The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.

  • 2 Cheap Dividend Stocks You Can Buy Right Now
    Motley Fool14 days ago

    2 Cheap Dividend Stocks You Can Buy Right Now

    These two drug stocks have a lot to offer income investors and value investors.